NEW YORK (360Dx) – Myriad Genetics said this week a top-five insurer has issued a positive medical policy decision for the Prolaris prostate cancer test. Myriad, through a spokesman, declined to identify the insurer. The firm noted that the positive coverage decision follows updated guidelines from the National Comprehensive Cancer Network for prostate cancer supporting Prolaris as a standard of care genetic test for men diagnosed with low and favorable-intermediate risk prostate cancer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.